NASDAQ: RNTX
Rein Therapeutics Inc Stock Ownership - Who owns Rein Therapeutics?

Insider buying vs selling

Have Rein Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James Brian WindsorPresident and CEO2024-12-05239$2.24
$535.36Buy
James Brian WindsorPresident and CEO2024-12-05161$2.25
$362.25Buy

1 of 1

RNTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RNTX insiders and whales buy or sell their stock.

RNTX Shareholders

What type of owners hold Rein Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Muneer A. Satter74.97%16,609,449$25.74MInsider
Reinhard J. Ambros11.51%2,549,982$3.95MInsider
Novartis Bioventures Ltd9.39%2,079,394$3.22MInsider
Of Texastexas Am Investment Managment Co University8.17%1,810,457$2.81MInsider
University Of Texastexas Am Investment Management Co7.88%1,746,549$2.71MInsider
Bios Capital Management LP7.63%1,690,751$2.62MInstitution
Brian M. Gallagher Jr.6.46%1,431,519$2.22MInsider
LV Management Group LLC4.94%1,094,987$1.70MInsider
Armen Shanafelt4.94%1,094,987$1.70MInsider
Excel Medical Fund LP4.59%1,016,100$1.57MInsider

1 of 3

RNTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNTX15.05%84.95%Net Buying
CGTX18.76%41.39%Net SellingNet Selling
KZR21.45%78.55%Net SellingNet Selling
ANTX39.55%60.45%Net SellingNet Selling
COEP0.37%99.63%

Rein Therapeutics Stock Ownership FAQ

Who owns Rein Therapeutics?

Rein Therapeutics (NASDAQ: RNTX) is owned by 27.06% institutional shareholders, 152.79% Rein Therapeutics insiders, and 0.00% retail investors. Muneer A. Satter is the largest individual Rein Therapeutics shareholder, owning 16.61M shares representing 74.97% of the company. Muneer A. Satter's Rein Therapeutics shares are currently valued at $24.75M.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.